NASDAQ:SANA Sana Biotechnology (SANA) Stock Price, News & Analysis → He Is Giving Away Bitcoin (From Crypto Swap Profits) (Ad) Free SANA Stock Alerts $7.56 +0.06 (+0.80%) (As of 05/10/2024 ET) Add Compare Share Share Today's Range$7.40▼$7.9750-Day Range$7.50▼$11.2752-Week Range$2.74▼$12.00Volume3.84 million shsAverage Volume1.98 million shsMarket Capitalization$1.67 billionP/E RatioN/ADividend YieldN/APrice Target$11.67 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Sana Biotechnology alerts: Email Address Sana Biotechnology MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.75 Rating ScoreUpside/Downside54.3% Upside$11.67 Price TargetShort InterestBearish20.85% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.28Based on 12 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.06) to ($0.95) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.17 out of 5 starsMedical Sector536th out of 921 stocksBiological Products, Except Diagnostic Industry80th out of 154 stocks 3.4 Analyst's Opinion Consensus RatingSana Biotechnology has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageSana Biotechnology has only been the subject of 2 research reports in the past 90 days.Read more about Sana Biotechnology's stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted20.85% of the float of Sana Biotechnology has been sold short.Short Interest Ratio / Days to CoverSana Biotechnology has a short interest ratio ("days to cover") of 12.5, which indicates bearish sentiment.Change versus previous monthShort interest in Sana Biotechnology has recently decreased by 4.00%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldSana Biotechnology does not currently pay a dividend.Dividend GrowthSana Biotechnology does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for SANA. Previous Next 2.4 News and Social Media Coverage News SentimentSana Biotechnology has a news sentiment score of 0.28. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.52 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 12 news articles for Sana Biotechnology this week, compared to 2 articles on an average week.Search Interest12 people have searched for SANA on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Sana Biotechnology to their MarketBeat watchlist in the last 30 days. This is a decrease of -83% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Sana Biotechnology insiders have not sold or bought any company stock.Percentage Held by Insiders34.90% of the stock of Sana Biotechnology is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions88.23% of the stock of Sana Biotechnology is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Sana Biotechnology's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Sana Biotechnology are expected to grow in the coming year, from ($1.06) to ($0.95) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Sana Biotechnology is -4.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Sana Biotechnology is -4.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSana Biotechnology has a P/B Ratio of 4.47. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Sana Biotechnology's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaThe Crypto 9-5 Escape PlanA brand-new guide from the host of one of the world's largest cryptocurrency podcasts lays out an action plan that could help you retire quickly and comfortably in today's crypto market.Click here to get instant access to the guide About Sana Biotechnology Stock (NASDAQ:SANA)Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others. The company's product candidates include SC291 that is used as allogeneic cell therapies for hematologic malignancies; ARDENT for a potential treatment for non-Hodgkin's lymphoma, and chronic lymphoblastic leukemia; GLEAM, to treat multiple autoimmune disorders that involve production of autoimmune antibodies, including lupus nephritis, extrarenal lupus, antineutrophil cytoplasmic antibody -associated vasculitis, and others. It is developing SC262 to treat patients with relapsed and/or refractory B-cell malignancies; SC255 for multiple myeloma treatment; SC379, a therapy for patients with certain central nervous system disorders healthy allogeneic glial progenitor cells; SC451, a product candidate to treat diabetes, with an initial focus on type 1 diabetes mellitus; and UP421 that reduces long-term exogenous insulin dependence. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.Read More SANA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SANA Stock News HeadlinesMay 10, 2024 | finance.yahoo.comSana Biotechnology Inc (SANA) Reports First Quarter 2024 Financial ResultsMay 9, 2024 | markets.businessinsider.comSana Biotechnology: Promising Clinical Studies and Breakthrough Potential in T1D TherapyMay 11, 2024 | Priority Gold (Ad)The 2024 Gold Rush: Unleashing Market PotentialWelcome to the financial rollercoaster of 2024, where inflation is persistent, stock markets are overinflated and volatile, global conflicts are intensifying, and the national debt is reaching new heights.May 9, 2024 | markets.businessinsider.comBuy Rating Affirmed for Sana Biotechnology Amidst Strong Clinical Progress and Solid FinancialsMay 8, 2024 | investorplace.comSANA Stock Earnings: Sana Biotechnology Meets EPS for Q1 2024May 8, 2024 | sfgate.comSana: Q1 Earnings SnapshotMay 8, 2024 | finance.yahoo.comSana Biotechnology Reports First Quarter 2024 Financial Results and Business UpdatesMay 6, 2024 | globenewswire.comSana Biotechnology to Present at May and June 2024 Investor ConferencesMay 11, 2024 | Priority Gold (Ad)The 2024 Gold Rush: Unleashing Market PotentialWelcome to the financial rollercoaster of 2024, where inflation is persistent, stock markets are overinflated and volatile, global conflicts are intensifying, and the national debt is reaching new heights.May 2, 2024 | finance.yahoo.comNvelop Therapeutics Announces Members of Its Scientific Advisory BoardMay 1, 2024 | finance.yahoo.comSana Biotechnology, Inc. (SANA) Stock Price, News, Quote & History - Yahoo FinanceMay 1, 2024 | americanbankingnews.com4D Molecular Therapeutics (NASDAQ:FDMT) & Sana Biotechnology (NASDAQ:SANA) Head-To-Head AnalysisApril 26, 2024 | msn.comTech Moves: Seattle tech vet Dave Parker named CEO of Entrepreneurs’ OrganizationApril 22, 2024 | bizjournals.comSana Biotechnology R&D leader Douglas Williams steps downApril 20, 2024 | investing.comSana Biotechnology EVP Williams resigns from R&D postMarch 17, 2024 | seekingalpha.comSana Biotechnology: Now In Overbought TerritoryMarch 16, 2024 | finance.yahoo.comSANA Apr 2024 15.000 callMarch 14, 2024 | finance.yahoo.comJ&J, Novo support Asgard’s push to make ‘in vivo’ cell therapiesMarch 11, 2024 | finance.yahoo.comDirector Patrick Yang Sells 25,000 Shares of Sana Biotechnology Inc (SANA)March 7, 2024 | finance.yahoo.comBaillie Gifford Bolsters Stake in Sana Biotechnology IncMarch 1, 2024 | markets.businessinsider.comSana Biotechnology: Buy Rating Affirmed Amid Anticipation of Clinical Breakthroughs and Hypoimmune Platform ValidationMarch 1, 2024 | markets.businessinsider.comSana Biotechnology: Promising Clinical Prospects and Buy Rating Justified by Upcoming Data ReadoutsMarch 1, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Privia Health Group (PRVA) and Sana Biotechnology (SANA)February 29, 2024 | globenewswire.comSana Biotechnology Reports Fourth Quarter and Full Year 2023 Financial Results and Business UpdatesFebruary 28, 2024 | globenewswire.comSana Biotechnology to Present at the Cowen 44th Annual Health Care ConferenceFebruary 19, 2024 | finance.yahoo.comInstitutional investors are Sana Biotechnology, Inc.'s (NASDAQ:SANA) biggest bettors and were rewarded after last week's US$521m market cap gainFebruary 18, 2024 | 247wallst.comInsider Buying: Taking a Controlling Stake in a Struggling Retailer?See More Headlines Receive SANA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sana Biotechnology and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/29/2024Today5/10/2024Next Earnings (Estimated)8/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:SANA CUSIPN/A CIK1770121 Websana.com Phone206-701-7914FaxN/AEmployees328Year FoundedN/APrice Target and Rating Average Stock Price Target$11.67 High Stock Price Target$15.00 Low Stock Price Target$8.00 Potential Upside/Downside+54.3%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($1.47) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-283,260,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-88.36% Return on Assets-47.89% Debt Debt-to-Equity RatioN/A Current Ratio3.31 Quick Ratio3.31 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.46 per share Price / Book5.18Miscellaneous Outstanding Shares220,450,000Free Float143,512,000Market Cap$1.67 billion OptionableOptionable Beta1.62 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesDr. Steven D. Harr M.D. (Age 54)President, CEO & Director Comp: $1.04MMs. Robin Andrulevich (Age 58)Executive VP & Chief People Officer Dr. Edward Rebar Ph.D. (Age 56)Head of Cell Engineering Mr. Paul Brunetta M.D.Senior VP and Head of Clinical & Translational ScienceMr. Christian Hordo M.B.A. (Age 41)Executive VP & Chief Business Officer Comp: $485.03kDr. Sonja Schrepfer M.D. (Age 49)Ph.D., Senior VP & Head of Hypoimmune Platform Dr. Terry Fry M.D. (Age 57)Senior VP & Head of T Cell Therapeutics Dr. Steven A. Goldman M.D. (Age 66)Ph.D., Senior VP & Head of CNS Therapy Ms. Farah AnwarHead of Development Operations & IDE LeaderDr. Gary Meininger M.D.Chief Medical OfficerMore ExecutivesKey CompetitorsApogee TherapeuticsNASDAQ:APGECG OncologyNASDAQ:CGONKymera TherapeuticsNASDAQ:KYMRRecursion PharmaceuticalsNASDAQ:RXRXVericelNASDAQ:VCELView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Bought 2,358,089 shares on 5/10/2024Ownership: 5.514%State Board of Administration of Florida Retirement SystemSold 9,700 shares on 5/9/2024Ownership: 0.008%ProShare Advisors LLCBought 4,210 shares on 5/8/2024Ownership: 0.015%Susquehanna Fundamental Investments LLCBought 134,309 shares on 5/7/2024Ownership: 0.061%SG Americas Securities LLCSold 12,857 shares on 5/7/2024Ownership: 0.005%View All Insider TransactionsView All Institutional Transactions SANA Stock Analysis - Frequently Asked Questions Should I buy or sell Sana Biotechnology stock right now? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sana Biotechnology in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" SANA shares. View SANA analyst ratings or view top-rated stocks. What is Sana Biotechnology's stock price target for 2024? 4 brokerages have issued 1-year target prices for Sana Biotechnology's stock. Their SANA share price targets range from $8.00 to $15.00. On average, they expect the company's stock price to reach $11.67 in the next twelve months. This suggests a possible upside of 54.3% from the stock's current price. View analysts price targets for SANA or view top-rated stocks among Wall Street analysts. How have SANA shares performed in 2024? Sana Biotechnology's stock was trading at $4.08 at the start of the year. Since then, SANA stock has increased by 85.3% and is now trading at $7.56. View the best growth stocks for 2024 here. When is Sana Biotechnology's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 1st 2024. View our SANA earnings forecast. How were Sana Biotechnology's earnings last quarter? Sana Biotechnology, Inc. (NASDAQ:SANA) announced its quarterly earnings results on Thursday, February, 29th. The company reported ($0.35) EPS for the quarter, topping analysts' consensus estimates of ($0.38) by $0.03. During the same period in the previous year, the company posted ($0.40) EPS. What ETFs hold Sana Biotechnology's stock? ETFs with the largest weight of Sana Biotechnology (NASDAQ:SANA) stock in their portfolio include Virtus LifeSci Biotech Clinical Trials ETF (BBC) and Global X Genomics & Biotechnology ETF (GNOM).WisdomTree BioRevolution Fund (WDNA). When did Sana Biotechnology IPO? Sana Biotechnology (SANA) raised $322 million in an initial public offering (IPO) on Thursday, February 4th 2021. The company issued 15,000,000 shares at a price of $20.00-$23.00 per share. Morgan Stanley, Goldman Sachs, J.P. Morgan and BofA Securities acted as the underwriters for the IPO. Who are Sana Biotechnology's major shareholders? Sana Biotechnology's stock is owned by many different institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (5.51%), Baillie Gifford & Co. (4.83%), Susquehanna Fundamental Investments LLC (0.06%), Susquehanna Portfolio Strategies LLC (0.04%), Los Angeles Capital Management LLC (0.03%) and Mirae Asset Global Investments Co. Ltd. (0.03%). Insiders that own company stock include Christian Hordo, James J Macdonald, Joshua H Bilenker, Patrick Y Yang, Robert Nelsen and Ventures Fund V Gener Flagship. View institutional ownership trends. How do I buy shares of Sana Biotechnology? Shares of SANA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:SANA) was last updated on 5/11/2024 by MarketBeat.com Staff From Our PartnersThe Crypto 9-5 Escape PlanCrypto 101 MediaDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsGlobal crypto currency reset (41 major banks signed up)Stansberry ResearchForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressHow Biden has already won 2024Porter & CompanyRSVP: Charles Payne’s Cash Flow WorkshopUnstoppable ProsperityThe “Next Bitcoin”? 10 CENT Crypto Set to ExplodeTrue Market InsidersThe ONE AI Stock to own now. (It’s not Nvidia.)Weiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sana Biotechnology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.